Ewing Sarcoma
57 programs · 54 companies
Programs
57
Companies
54
Trials
59
MOAs
37
CDK4/6iAnti-AβBETiMALT1iPARPiDLL3 ADCUSP1iTROP-2 ADCBTKiGLP-1ag
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Phase 1/2 | BET | ||
| LLY-8369 | Approved | Menin | ||
| LLY-1592 | NDA/BLA | FGFR | ||
| NVS-3297 | Preclinical | CDK2 | ||
| MRK-3732 | Phase 1 | TYK2 | ||
| Rimamavacamten | Phase 1 | PI3Kα | ||
| Datozumab | Phase 1 | B7-H3 | ||
| Bemazumab | Phase 1 | VEGF | ||
| Ivosotorasib | Preclinical | CD38 | ||
| ARG-1250 | Phase 2 | C5 | ||
| 180-3597 | Preclinical | SHP2 | ||
| BEA-2615 | Phase 3 | PRMT5 | ||
| Nidarelsin | Phase 2/3 | RET | ||
| Zoriosocimab | Phase 3 | BCL-2 | ||
| NVA-5991 | Phase 1 | ALK | ||
| Fixamavacamten | Phase 2 | SOS1 | ||
| Mavucagene | Preclinical | C5 | ||
| UCS-IIT-677 | Phase 2/3 | IL-13 | ||
| GIM-IIT-628 | Phase 2/3 | PSMA | ||
| MIR-8648 | Phase 1/2 | GLP-1R | ||
| VES-7360 | Approved | MET | ||
| ASM-4182 | Phase 2 | KRASG12C | ||
| IMV-6044 | Phase 1/2 | BCMA | ||
| FLA-9061 | NDA/BLA | JAK2 | ||
| Lisotapinarof | Approved | IL-17A | ||
| ADI-2736 | Preclinical | PD-1 | ||
| TRV-9080 | Phase 1/2 | IL-13 | ||
| Voxasotorasib | Phase 3 | CD38 | ||
| Polatuximab | Phase 1 | C5 | ||
| 601-209 | Phase 2/3 | TYK2 | ||
| SCI-8054 | Phase 2/3 | PRMT5 | ||
| MYO-9608 | NDA/BLA | APOC3 | ||
| TES-8356 | NDA/BLA | MET | ||
| LAE-3866 | Phase 1/2 | FXIa | ||
| 269-7185 | Preclinical | SOS1 | ||
| Capizanubrutinib | Preclinical | KRASG12C | ||
| INT-5527 | Phase 2 | PD-L1 | ||
| FRE-IIT-854 | Phase 1/2 | FGFR | ||
| 415-3897 | Phase 3 | GLP-1R | ||
| Pexatenlimab | Approved | EZH2 | ||
| CUR-8000 | Phase 2 | Aβ | ||
| ACH-7772 | Phase 1 | C5 | ||
| MRK-7986 | Phase 1/2 | WRN | ||
| Tezecapivasertib | Phase 2 | Nectin-4 | ||
| Olpazumab | Approved | CD19 | ||
| PHL-685 | Approved | USP1 | ||
| ERY-9084 | NDA/BLA | SHP2 | ||
| ESC-2069 | Phase 1/2 | FGFR | ||
| AJA-5085 | Preclinical | TIGIT | ||
| Gelinaritide | Phase 1/2 | FXIa | ||
| Tiraderotide | Phase 2 | BTK | ||
| BIO-IIT-514 | Approved | USP1 | ||
| TEV-6161 | Preclinical | PARP | ||
| 002-8467 | Phase 1/2 | SHP2 | ||
| Liramavacamten | Phase 1 | CD38 | ||
| Fixazanubrutinib | Preclinical | EZH2 | ||
| VCY-7977 | Phase 3 | RET |
Trials (59)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06519483 | LLY-8369 | Approved | Recruiting |
| NCT04524281 | LLY-1592 | NDA/BLA | Terminated |
| NCT03668579 | MRK-3732 | Phase 1 | Terminated |
| NCT04427674 | MRK-3732 | Phase 1 | Active |
| NCT06114587 | Rimamavacamten | Phase 1 | Recruiting |
| NCT04855789 | ARG-1250 | Phase 2 | Recruiting |
| NCT03476152 | ARG-1250 | Phase 2 | Active |
| NCT05560121 | 180-3597 | Preclinical | Active |
| NCT04285528 | BEA-2615 | Phase 3 | Not yet recr... |
| NCT05920386 | Nidarelsin | Phase 2/3 | Not yet recr... |
| NCT05395433 | Zoriosocimab | Phase 3 | Completed |
| NCT06157785 | Zoriosocimab | Phase 3 | Active |
| NCT07292453 | NVA-5991 | Phase 1 | Not yet recr... |
| NCT03830842 | NVA-5991 | Phase 1 | Recruiting |
| NCT05321304 | Fixamavacamten | Phase 2 | Completed |
| NCT06130608 | UCS-IIT-677 | Phase 2/3 | Terminated |
| NCT03367456 | GIM-IIT-628 | Phase 2/3 | Completed |
| NCT07224968 | ASM-4182 | Phase 2 | Recruiting |
| NCT06320111 | IMV-6044 | Phase 1/2 | Active |
| NCT06964685 | Lisotapinarof | Approved | Not yet recr... |